Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Bicalutamide does not raise transaminases in comparison to alternative anti-androgen regimens among transfeminine adolescents and young adults: a retrospective cohort study

Katie Burgener, Brian DeBosch, Jinli Wang, Christopher Lewis, View ORCID ProfileCynthia Herrick
doi: https://doi.org/10.1101/2024.02.21.24302999
Katie Burgener
aDepartment of Pediatrics, Division of Endocrinology and Diabetes, Washington University in St. Louis, St. Louis, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brian DeBosch
bDepartment of Pediatrics, Division of Gastroenterology, Hepatology and Nutrition, Washington University in St. Louis, St. Louis, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jinli Wang
cDepartment of Biostatistics, Washington University in St. Louis, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher Lewis
aDepartment of Pediatrics, Division of Endocrinology and Diabetes, Washington University in St. Louis, St. Louis, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cynthia Herrick
dDepartment of Internal Medicine, Division of Endocrinology, Diabetes, and Lipid Metabolism Research, Washington University in St. Louis, St. Louis, United States
eDepartment of Surgery, Division of Public Health Sciences, Washington University in St. Louis, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Cynthia Herrick
  • For correspondence: herrickc{at}wustl.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Bicalutamide is a potential anti-androgen for transgender individuals with feminizing embodiment goals, but use has been limited because of hepatotoxicity in cisgender men with prostate cancer. This study compared transaminase changes in transfeminine adolescents and young adults (AYA) using low-dose bicalutamide with individuals using other methods of androgen blockade.

Methods A retrospective analysis was conducted using electronic health record data for patients starting gender affirming hormone therapy with at least 10 months of follow-up data between 2015 and 2023. Linear mixed models compared change in ALT and AST from baseline and maximum ALT and AST values in bicalutamide and comparison groups. Secondary outcomes included % individuals with ALT and AST elevation more than 1, 2, or 3 times the upper limit of normal (ULN) (Fisher’s exact test), standardized mean estradiol dose by group (t test), and Tanner staging of breast tissue by group (Fisher’s exact test).

Results Eighty-four transfeminine AYA (median age 18) taking bicalutamide were compared to 69 transfeminine AYA (median age 19) taking GnRH agonists, spironolactone or no agent in addition to estradiol. In linear mixed models adjusted for baseline age, BMI, baseline ALT or AST, and alcohol use, there was no difference in delta or maximum ALT or AST in bicalutamide and comparison groups. No individuals had an AST or ALT level > 3x ULN. Estradiol doses and Tanner stages were similar between groups in a subgroup analysis of individuals receiving pediatric care.

Conclusion Bicalutamide was not associated with significant change in transaminases as compared with other anti-androgen regimens over one year. Bicalutamide appears to be a safe anti-androgen for transfeminine individuals at low dose with close monitoring and deserves further study.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

CJH completed this work while supported by a career development award from the NICHD (K23HD096204).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The Washington University Human Research Protection office gave ethical approval for this work.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Data Availability

All data produced in the present study are available upon reasonable request to the authors.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted February 23, 2024.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Bicalutamide does not raise transaminases in comparison to alternative anti-androgen regimens among transfeminine adolescents and young adults: a retrospective cohort study
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Bicalutamide does not raise transaminases in comparison to alternative anti-androgen regimens among transfeminine adolescents and young adults: a retrospective cohort study
Katie Burgener, Brian DeBosch, Jinli Wang, Christopher Lewis, Cynthia Herrick
medRxiv 2024.02.21.24302999; doi: https://doi.org/10.1101/2024.02.21.24302999
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Bicalutamide does not raise transaminases in comparison to alternative anti-androgen regimens among transfeminine adolescents and young adults: a retrospective cohort study
Katie Burgener, Brian DeBosch, Jinli Wang, Christopher Lewis, Cynthia Herrick
medRxiv 2024.02.21.24302999; doi: https://doi.org/10.1101/2024.02.21.24302999

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Endocrinology (including Diabetes Mellitus and Metabolic Disease)
Subject Areas
All Articles
  • Addiction Medicine (427)
  • Allergy and Immunology (753)
  • Anesthesia (220)
  • Cardiovascular Medicine (3281)
  • Dentistry and Oral Medicine (362)
  • Dermatology (274)
  • Emergency Medicine (478)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1164)
  • Epidemiology (13336)
  • Forensic Medicine (19)
  • Gastroenterology (896)
  • Genetic and Genomic Medicine (5127)
  • Geriatric Medicine (479)
  • Health Economics (780)
  • Health Informatics (3250)
  • Health Policy (1137)
  • Health Systems and Quality Improvement (1189)
  • Hematology (427)
  • HIV/AIDS (1012)
  • Infectious Diseases (except HIV/AIDS) (14611)
  • Intensive Care and Critical Care Medicine (908)
  • Medical Education (475)
  • Medical Ethics (126)
  • Nephrology (521)
  • Neurology (4898)
  • Nursing (261)
  • Nutrition (725)
  • Obstetrics and Gynecology (879)
  • Occupational and Environmental Health (795)
  • Oncology (2515)
  • Ophthalmology (722)
  • Orthopedics (280)
  • Otolaryngology (346)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (537)
  • Pediatrics (1297)
  • Pharmacology and Therapeutics (548)
  • Primary Care Research (554)
  • Psychiatry and Clinical Psychology (4189)
  • Public and Global Health (7482)
  • Radiology and Imaging (1700)
  • Rehabilitation Medicine and Physical Therapy (1010)
  • Respiratory Medicine (979)
  • Rheumatology (478)
  • Sexual and Reproductive Health (493)
  • Sports Medicine (424)
  • Surgery (545)
  • Toxicology (71)
  • Transplantation (235)
  • Urology (203)